Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Goodwill & Intangibles: 2021-2024

Historic Goodwill & Intangibles for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $16.2 million.

  • Kiniksa Pharmaceuticals International's Goodwill & Intangibles fell 6.06% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year decrease of 6.06%. This contributed to the annual value of $16.2 million for FY2024, which is 18.75% down from last year.
  • As of FY2024, Kiniksa Pharmaceuticals International's Goodwill & Intangibles stood at $16.2 million, which was down 18.75% from $20.0 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Goodwill & Intangibles ranged from a high of $20.0 million in FY2021 and a low of $16.2 million during FY2024.
  • Its 3-year average for Goodwill & Intangibles is $18.8 million, with a median of $20.0 million in 2023.
  • Data for Kiniksa Pharmaceuticals International's Goodwill & Intangibles shows a maximum YoY declined of 18.75% (in 2024) over the last 5 years.
  • Yearly analysis of 4 years shows Kiniksa Pharmaceuticals International's Goodwill & Intangibles stood at $20.0 million in 2021, then remained steady at $20.0 million in 2022, then remained steady at $20.0 million in 2023, then dropped by 18.75% to $16.2 million in 2024.